The FDA has asked manufacturers of GLP-1 weight loss drugs to remove warnings about the potential risk of suicidal thoughts.[1] On December 22, 2025, the FDA approved the first oral GLP-1 drug for the treatment of obesity, Novo Nordisk's Wegovy tablet.[1][4] This tablet is taken once a day and achieves weight loss results comparable to the injectable version of Wegova.[1] In the OASIS 4 clinical trial, 7 percent of participants discontinued treatment due to side effects, compared to 6 percent in the placebo group.[1] The most common side effects include nausea, vomiting, diarrhea, and constipation, which are often temporary.[1] GLP-1 drugs are not suitable for patients with a history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2 syndrome, or hypersensitivity to semaglutide.[1] They are not recommended during pregnancy or breastfeeding.[1] Other approvals include Eli Lilly's expected orforglipron tablet in 2026 and Novo Nordisk's CagriSema, where participants lost an average of 20.4 percent of their body weight after 68 weeks.[2]